Steve Furlong: So, Adam, on the reimbursement side, I think with United Health Care dropping from four to two, it is a great sign. Many of the other payers follow what United Health Care does. As recently as last fall, Aetna went from two to four, because that’s where UnitedHealthcare was. So, I — we are hoping that the other payers drop their requirements to and follow United Health Care’s lead. Quite honestly, there are plenty of patients out there that have failed four drugs, so we’re not in a — there’s no shortage it does expand the market when we drop it down to two. And I think our hope now is that United and the other payers make it easier to go through the prior authorization process, so it does expand our market, it does help our patients now we need to help our accounts with simplifying prior authorization.
Operator: Thank you. Our next question comes from Margaret Kaczor with William Blair. Your line is open.
Margaret Kaczor: Hey, good morning. Thanks for taking the question.
Keith Sullivan: Hey, Margaret.
Margaret Kaczor: I’m going to chime in with all my colleagues on the guidance side, so apologies for that. But I guess one more, it’s kind of a simple one. I guess what gets you to the high and the low-end of the range, because it’s obviously quite broad. So, and more specifically, I guess, do you need Greenbrook to improve to get to that high-end of the range? Or can the base do that? And then kind of a similar question on the low-end of that range?
Steve Furlong: No, I don’t, Margaret, I think we need some contribution from Greenbrook and based on the release in their revenue haircut related to the 50 stores, we don’t need any incremental growth from Greenbrook to get to either one of those figures. So that should really be the growth from the other segments and would represent that 20% target.
Margaret Kaczor: Okay. So sorry, yes, the 20% growth from the other figures, I mean, again, it’s a wider range, so is 20%, kind of, the midpoint of the range. And then the two, kind of, high and low-end, you know, depending if the base is better or if we’re in good or better or worse. Am I understanding that right?
Steve Furlong: Yes, I think it represents the midpoint.
Margaret Kaczor: Okay, perfect. And then I wanted to follow-up on the strategies, because you spent a lot of time both at the beginning and the end kind of walking through that in 2022 and kind of the goals for 2023, PHQ-10, then a fews, et cetera. Is 2023 a year where those efforts I guess can scale on a broader basis where you can get maybe 2 times or 3 times or 20% of the base through those? Or is it just kind of more of a continuation with some solid growth and engagement?
Keith Sullivan: Thanks for the question, Margaret. I think if we look at the NSU, we have seen the accounts that come through NSU adopt almost all of our programs on a universal basis. And as a result, their business has gone up. So, I think that we — our focus is to try and get more of our accounts through the NeuroStar University program. And I think that we have seen our number of accounts that are using the PHQ-10s just in the fourth quarter went from a little over $300 million to $450 million. So it is gaining traction, so I think 2023 is going to be a standout year for it. And I think that we can anticipate some that, that is going to be what’s going to help us drive the growth.
Margaret Kaczor: Okay, great. Thank you, guys.
Operator: Thank you. Our next question comes from Daniel Stauder with JMP Securities. Your line is open.
